Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin for depression in Parkinson's disease
NCT03482882Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pimavanserin in major depressive disorder (MDD), sponsored by Acadia Pharmaceuticals. Primary endpoint: Change From Baseline in Hamilton Depression Scale -17 Items Total Score at 8 weeks. Started Mar 2018; status: completed.
02
Drugs
pimavanserin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03482882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03482882.